COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
Objectives We aimed to investigate the role of rheumatoid arthritis (RA) with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD) exposure in COVID-19 outcomes.Methods Our study retrieved data from the US Collaborative Network in TriNetX between 1 January 2018 and 31 Dec...
I tiakina i:
| Ngā kaituhi matua: | , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMJ Publishing Group
2023-07-01
|
| Rangatū: | RMD Open |
| Urunga tuihono: | https://rmdopen.bmj.com/content/9/3/e003038.full |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|